Trial Profile
A Randomized, Double-Blind Study of the Effect of Treatment Duration and Dose of PEGASYS on HBeAg Seroconversion and Safety in Patients With HBeAg Positive Chronic Hepatitis B.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms NEPTUNE
- Sponsors Roche
- 09 Mar 2018 Results assessing seroconversion rates 5 years after completion of treatment, were published in the Alimentary Pharmacology and Therapeutics.
- 01 Nov 2011 Results published in Hepatology.
- 19 Jul 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov. (Parent trial: NCT00435825).